NCT05379985
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: KRAS
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes: Patient must have an advanced solid tumor with KRAS p.G12A, KRAS p.G12D, KRAS p.G12R, KRAS p.G12S, or KRAS p.G12V mutations
Exclusions: Patients with tumors harboring the KRAS p.G12C mutation; Patients with known or suspected leptomeningeal or brain metastases
https://ClinicalTrials.gov/show/NCT05379985